Pro-inflammatory signaling in lung injury

Pro-inflammatory signaling in lung injury describes the coordinated molecular response to pulmonary insults, such as infection, trauma, or aspiration, which leads to Acute Lung Injury (ALI) and its more severe form, Acute Respiratory Distress Syndrome (ARDS) (Matthay et al., Nature Reviews Disease Primers, 2019). This signaling is typically initiated by the activation of pattern recognition receptors, such as Toll-like receptor 4 (TLR4), by pathogens or endogenous danger signals (Butt et al., Archives of Pathology & Laboratory Medicine, 2016). Activation of these receptors triggers downstream cascades involving the NLRP3 inflammasome and the transcription factor NF-kappaB, leading to the massive production of pro-inflammatory cytokines including TNF-alpha, IL-1 beta, and IL-6 (Meduri et al., Intensive Care Medicine, 2020). These cytokines promote the recruitment and activation of neutrophils, which release proteases and reactive oxygen species that damage the alveolar-capillary barrier, leading to pulmonary edema and impaired gas exchange (Sarma & Ward, Journal of Biomedical Science, 2011). Therapeutic interventions targeting this signaling include broad-spectrum anti-inflammatories like corticosteroids and targeted biologics such as IL-6 receptor antagonists or JAK inhibitors, which aim to mitigate the 'cytokine storm' and prevent multi-organ failure (Xu et al., The Lancet Respiratory Medicine, 2020).

Other names

Acute lung injury signaling cascadeARDS inflammatory pathwayPulmonary cytokine stormLung inflammatory signalingAlveolar inflammatory response

Modulation of the inflammatory cascade through the inhibition of specific cytokines (e.g., IL-6, TNF-alpha), cytokine receptors, or intracellular signaling molecules (e.g., JAK, NF-kappaB) to reduce pulmonary inflammation and vascular leakage.